🎙️✨ Melinda Knows Best at AAD Denver: Hands Down, Chronic Hand Eczema Is Getting a New Playbook 🖐️

Live from AAD 2026 in Denver 🏔️, a podcast favorite, Melinda Knows Best returns with Dr. Melinda Gooderham for a true post-game analysis🏀 of new chronic hand eczema data — and yes, this one is all about helping hands get back to doing what hands do best: opening jars 🥜, buttoning shirts 👔, holding coffee cups ☕, and generally not letting everyday life feel just like a clinical endpoint.

In this episode, we break down new pooled post-hoc data evaluating delgocitinib cream versus vehicle in adults with moderate-to-severe chronic hand eczema, with a practical twist: does prior systemic therapy exposure matter for patient success, especially when it comes to pain and itch? 🤔

We dive into:

• Does this data push delgocitinib earlier in the treatment algorithm for Melinda?
• What are the biggest critiques or caveats a dermatologist should keep in mind when looking at this data?
• Who is the real-world patient you would think about tomorrow after seeing this poster

Well the chronic hand eczema treatment ladder may not be a one-way escalator anymore. 🪜🔄

Dr. Gooderham brings the real-world lens 👩‍⚕️: patients do not just want almost clear skin on a study scale — they want to work, cook, dress, sleep, and live without painful, itchy, fissured hands getting in the way.

Because when it comes to chronic hand eczema, sometimes the most meaningful outcome is being able to open the peanut butter jar without negotiating with your skin first. 🥜😅

Learning objectives 📚
By the end of this episode, listeners will be able to:

1. Summarize new AAD 2026 data evaluating delgocitinib cream in moderate-to-severe chronic hand eczema based on prior systemic therapy exposure.
2. Compare response patterns in systemic-naïve versus systemic-experienced patients.
3. Discuss the real-world clinical relevance of early itch and pain improvement in chronic hand eczema.
4. Identify key caveats of the analysis, including its post-hoc design, subgroup size, and 16-week timeframe.
5. Consider how delgocitinib may fit into evolving treatment algorithms for chronic hand eczema.

#SkinAndJointsPodcast #MelindaKnowsBest #AAD2026 #ChronicHandEczema #HandEczema #EczemaCare #Dermatology #DermatologyPodcast #Delgocitinib #MedicalEducation #HCPeducation #DermTwitter #AADDenver #SkinScience #TopicalTherapy #RealWorldDermatology #IGA #HESD #itch #pain

Episode supported by and IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️✨ Isotretinoin + Clascoterone: Acne’s New Power Couple?

When acne gets severe, isotretinoin usually enters the chat as the big gun.💥
But what happens when you pair it with topical clascoterone — the anti-androgen sidekick targeting the sebaceous gland from another angle?

In this episode, we break down new real-world data from a multi-centre retrospective study comparing oral isotretinoin monotherapy versus combination isotretinoin + topical clascoterone for severe acne vulgaris and what the implications are for clinic.

And yes — the combo arm brought some serious main-character energy.

Our expert guests unpack what this could mean in clinic:
✨ faster clearance
✨ improved tolerability
✨ hormonal acne considerations
✨ patient adherence realities
✨ the ever-important goal of preventing scars before they happen

Because in acne care, almost clear is nice… but clear-clear is the assignment. ✅

This conversation dives into the practical side: When should clascoterone be added? Which patients may benefit most? How do we keep regimens simple for younger patients already juggling isotretinoin, labs, moisturizers, sunscreen, and TikTok skincare detox?

Learning objectives:
✅ Review emerging data comparing isotretinoin monotherapy with isotretinoin plus topical clascoterone in severe acne vulgaris
✅ Discuss the potential clinical relevance of combination therapy for clearance, tolerability, and patient experience
✅ Explore practical approaches to integrating clascoterone into isotretinoin treatment plans
✅ Consider real-world limitations of retrospective data, including confounders, dosing variation, skincare use, and patient selection
✅ Reframe acne treatment goals beyond lesion counts to include scarring prevention, satisfaction, and long-term disease control

🎧 AAD 2026 coverage from the Mile High City. Special thanks Dr. Mohannad Abu-Hilal.

#SkinAndJointsPodcast #AAD2026 #Dermatology #Acne #AcneVulgaris #Isotretinoin #Clascoterone #Winlevi #DermTwitter #MedEd #DermatologyEducation #SevereAcne #AcneScarring #SkinHealth #ClinicalDermatology #Vodcast #Podcast #HealthcareEducation

ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

🎙️✨ New Acne Data Just Dropped — and We’re Bringing the Post-Game Analysis from AAD 2026! 🏀

Live from Denver — the Mile High City — the Skin and Joints Podcast is breaking down new 52-week real-world acne data exploring the impact of clascoterone 1% on sebum reduction, acne improvement, tolerability, and what it actually means in day-to-day dermatology practice.

Because let’s be honest: in acne care, it’s not just about lesion counts. Patients care about oiliness, shine, pores, irritation, post-inflammatory marks, and whether their treatment routine feels like a science experiment before bed.

In this episode, Dr. Renée A. Beach and Dr. Irina Oroz (and a mystery guest co-host ;)) join the conversation to unpack the clinical relevance of the data — and why “treat-to-happy” might just be the endpoint patients really care about.

We also get into the practical side:
✅How do you layer clascoterone with retinoids?
✅What does sebum reduction actually mean in clinic?
✅Is “zero irritation” too good to be true — or reflective of real-world experience?
✅And most importantly… is it pronounced sebometer or sebumeter?

From male acne patients who now have a topical anti-androgen option, to patients who have tried everything, to those who need a tolerable long-term acne strategy — this episode explores where the data meets the real world.

Learning Objectives:
✅ Review new 52-week data on clascoterone 1% and sebum reduction in acne
✅ Discuss the clinical relevance of sebum, shine, oiliness, and patient-reported treatment success
✅ Evaluate long-term acne outcomes including IGA success, inflammatory and non-inflammatory lesion reduction, and tolerability
✅ Explore practical strategies for layering clascoterone with retinoids, benzoyl peroxide, and combo topical therapies
✅ Identify patient profiles who may benefit from topical anti-androgen therapy in real-world practice

ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

Supported by an IME Grant from SUN Pharma.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.